血漿分画製剤の世界市場：アルブミン製剤、免疫グロブリン製剤、第VIII因子、プロテアーゼ阻害薬...市場調査レポートについてご紹介

1 Introduction (Page No. – 15)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology (Page No. – 18)
2.1 Research Approach
2.1.1 Secondary Sources
2.1.2 Key Data From Secondary Sources
2.1.3 Primary Sources
2.1.4 Key Data From Primary Sources
2.1.5 Key Industry Insights
2.2 Market Size Estimation
2.3 Market Breakdown and Data Triangulation
2.4 Market Share Estimation

3 Executive Summary (Page No. – 26)

4 Premium Insights (Page No. – 32)
4.1 Market Overview
4.2 Asia-Pacific Plasma Fractionation Market
4.3 Plasma Fractionation Market: Geographic Growth Opportunities
4.4 Plasma Fractionation Market: Geographic Mix
4.5 Plasma Fractionation Market: Developing vs Developed Countries

5 Market Overview (Page No. – 37)
5.1 Introduction
5.2 Market Dynamics
5.3 Key Market Drivers
5.3.1 Growing Use of Immunoglobulins in Various Therapeutic Areas
5.3.2 Rise in the Aging Population Across the Globe
5.3.3 Growing Prevalence of Respiratory Diseases and Aatd Driving the Uptake of Alpha-1 Antitrypsin
5.3.4 Increase in Plasma Collection
5.4 Key Market Restraints
5.4.1 High Cost and Limited Reimbursements
5.4.2 Stringent Government Regulations
5.4.3 Emergence of Recombinant Alternatives
5.5 Key Market Opportunities
5.5.1 Increasing Number of Hemophilic Patients
5.6 Key Challenges
5.6.1 Pricing Pressure Faced By Prominent Players in the Market

6 Industry Insights (Page No. – 47)
6.1 Introduction
6.2 Key Industry Trends
6.2.1 Focus on Increasing Fractionation CAPACities and Geographical Expansions
6.2.2 New Indications for Plasma Products
6.2.3 Rising Adoption of SCIG
6.2.4 Increasing Number of Fractionator-Owned Plasma Collection Centers
6.2.5 Growing Plasma Products Market in China
6.2.6 Increasing Focus of Plasma Fractionators Towards Manufacturing and Development of Recombinant Factors
6.3 Porter’s Five Forces Analysis
6.3.1 Threat of New Entrants
6.3.2 Threat of Substitutes
6.3.3 Bargaining Power of Suppliers
6.3.4 Bargaining Power of Buyers
6.3.5 Intensity of Competitive Rivalry

7 Global Plasma Fractionation Market, By Product (Page No. – 57)
7.1 Introduction
7.2 Fractionation Process
7.3 Immunoglobulin
7.3.1 Intravenous Immunoglobulin
7.3.2 Subcutaneous Immunoglobulin
7.3.3 Other Immunoglobulins
7.4 Coagulation Factor Concentrates
7.4.1 Factor VIII
7.4.2 Factor IX
7.4.3 Factor XIII
7.4.4 Prothrombin Complex Concentrates
7.4.5 Von Willebrand Factor (VWF)
7.4.6 Fibrinogen Concentrates
7.5 Albumin
7.6 Protease Inhibitors
7.7 Other Plasma Products

8 Global Plasma Fractionation Market, By Application (Page No. – 77)
8.1 Introduction
8.2 Neurology
8.3 Immunology
8.4 Hematology
8.5 Critical Care
8.6 Pulmonology
8.7 Hemato-Oncology
8.8 Rheumatology
8.9 Other Applications

9 Global Plasma Fractionation Market, By End User (Page No. – 94)
9.1 Introduction
9.2 Hospitals and Clinics
9.3 Clinical Research Laboratories
9.4 Academic Institutes

10 Global Plasma Fractionation Market, By Region (Page No. – 99)
10.1 Introduction
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 France
10.3.3 Italy
10.3.4 Spain
10.3.5 U.K.
10.3.6 Rest of Europe (RoE)
10.4 Asia-Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Rest of Asia-Pacific (Ro-APAC)
10.5 Rest of the World (RoW)
10.5.1 Latin America
10.5.2 Middle East and Africa

11 Competitive Landscape (Page No. – 168)
11.1 Overview
11.2 Market Share Analysis
11.3 Competitive Situation and Trends
11.3.1 Expansions
11.3.2 Agreements, Collaborations, and Partnerships
11.3.3 New Product Launches
11.3.4 Acquisitions

12 Company Profiles (Page No. – 176)
12.1 Introduction
12.2 CSL Ltd.
12.2.1 Business Overview
12.2.2 Products Offered
12.2.3 Recent Developments
12.2.4 MnM View
12.3 Grifols S.A.
12.3.1 Business Overview
12.3.2 Products Offered
12.3.3 Recent Developments
12.3.4 MnM View
12.4 Baxalta Incorporated
12.4.1 Business Overview
12.4.2 Products Offered
12.4.3 Recent Developments
12.4.4 MnM View
12.5 Octapharma AG
12.5.1 Business Overview
12.5.2 Products Offered
12.5.3 Recent Developments
12.5.4 MnM View
12.6 Kedrion S.P.A
12.6.1 Business Overview
12.6.2 Products Offered
12.6.3 Recent Developments
12.6.4 MnM View
12.7 China Biologic Products, Inc.
12.7.1 Business Overview
12.7.2 Products Offered
12.7.3 Recent Developments
12.8 Biotest AG
12.8.1 Business Overview
12.8.2 Products Offered
12.8.3 Recent Developments
12.9 LFB S.A.
12.9.1 Business Overview
12.9.2 Products Offered
12.9.3 Recent Developments
12.10 Bio Product Laboratory Ltd. (BPL)
12.10.1 Business Overview
12.10.2 Products Offered
12.10.3 Recent Developments
12.11 Sanquin
12.11.1 Business Overview
12.11.2 Products Offered

13 Appendix (Page No. – 197)
13.1 Insights of Industry Experts
13.2 Discussion Guide
13.3 Other Developments
13.4 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.5 Available Customizations
13.6 Introducing RT: Real-Time Market Intelligence
13.7 Related Reports